Drug Trial Radar · NCT01590446
A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers
Last checked: Nov 19, 2026Latest source record: Jun 11, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
74
Planned (sponsor's estimate)
Start
Feb 2012
Primary completion
Jun 2012
Study completion Jun 2012
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- May 3, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 22 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure how much of the study drug gets into the blood- stream and how long it takes the body to get rid of it when given as a single dose. Information about any side effects that may occur will also be collected.
Conditions
- Achondroplasia
Interventions
BMN 111Drug
SC injection, Part 1 single dose and Part 2 multiple dose.
Normal SalineDrug
SC injection, Part 1 single dose and Part 2 multiple dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety based on vitals signsTime frame: Daily throughout the study Assessed for approximately 8 days following each single dose in Part 1, and for approximately 24 days following each daily dose in Part 2
- Safety based on adverse eventsTime frame: Daily throughout the study Assessed for approximately 8 days following each single dose in Part 1, and for approximately 24 days following each daily dose in Part 2
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Covance CRU Inc.
Evansville, Indiana
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.